Ultragenyx Pharmaceutical Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 8 | -$1.93 | -$1.58 | -$1.75 |
| Q2 2024 | 8 | -$1.83 | -$1.50 | -$1.66 |
| Q3 2024 | 4 | -$1.64 | -$1.34 | -$1.48 |
| Q4 2024 | 11 | -$1.80 | -$1.10 | -$1.34 |
| Q1 2025 | 8 | -$1.58 | -$1.06 | -$1.36 |
| Q2 2025 | 5 | -$1.42 | -$1.16 | -$1.29 |
| Q3 2025 | 4 | -$1.39 | -$1.13 | -$1.26 |
| Q4 2025 | 5 | -$1.29 | -$1.06 | -$1.17 |
| Q1 2026 | 3 | -$0.32 | -$0.26 | -$0.29 |
| Q2 2026 | 4 | -$0.20 | -$0.16 | -$0.18 |
| Q3 2026 | 3 | -$0.15 | -$0.13 | -$0.14 |
| Q4 2026 | 4 | $0.00 | $0.00 | $0.00 |
Ultragenyx Pharmaceutical Inc. Earnings Date And Information
Ultragenyx Pharmaceutical Inc. last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-1.4 earnings per share for the quarter, topping analysts' consensus estimates of $-1.45 by $0.05. The company had revenue of 139.49 M for the quarter and had revenue of 434.25 M for the year. Ultragenyx Pharmaceutical Inc. has generated $-8 earnings per share over the last year ($-8.25 diluted earnings per share) and currently has a price-to-earnings ratio of -8.07. Ultragenyx Pharmaceutical Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based on prior year's report dates.
Ultragenyx Pharmaceutical Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2024 | Q3 2024 | -$1.40 | $135.28 M | $139.49 M | ||
| 08/01/2024 | Q2 2024 | -$1.52 | $123.20 M | $147.03 M | ||
| 05/02/2024 | Q1 2024 | -$2.03 | $108.83 M | |||
| 02/21/2024 | Q4 2023 | -$1.52 | $127.39 M | |||
| 11/02/2023 | Q3 2023 | -$2.23 | $109.60 M | $98.05 M | ||
| 08/03/2023 | Q2 2023 | -$2.25 | $104.81 M | $108.31 M | ||
| 05/04/2023 | Q1 2023 | -$2.33 | $100.50 M | |||
| 02/16/2023 | Q4 2022 | -$2.16 | $103.35 M | |||
| 11/02/2022 | Q3 2022 | -$3.50 | $96.46 M | $90.70 M | ||
| 07/28/2022 | Q2 2022 | -$2.26 | $87.78 M | $89.34 M | ||
| 05/05/2022 | Q1 2022 | -$2.19 | $79.94 M | |||
| 02/15/2022 | Q4 2021 | -$1.79 | $83.39 M | |||
| 11/02/2021 | Q3 2021 | -$1.08 | $81.55 M | $81.65 M | ||
| 08/02/2021 | Q2 2021 | -$1.81 | $85.87 M | $86.98 M | ||
| 05/04/2021 | Q1 2021 | -$2.03 | $99.40 M | |||
| 02/11/2021 | Q4 2020 | -$0.37 | $91.54 M | |||
| 10/27/2020 | Q3 2020 | -$1.24 | -$1.13 | 0.11 | $54.96 M | $81.47 M |
| 07/31/2020 | Q2 2020 | -$1.56 | $0.41 | 1.97 | $39.34 M | $61.71 M |
| 05/06/2020 | Q1 2020 | -$2.05 | $36.31 M | |||
| 02/13/2020 | Q4 2019 | -$1.62 | $35.59 M |
Ultragenyx Pharmaceutical Inc. Earnings: Frequently Asked Questions
-
When is Ultragenyx Pharmaceutical Inc.'s earnings date?
Ultragenyx Pharmaceutical Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based off last year's report dates.
-
Did Ultragenyx Pharmaceutical Inc. beat their earnings estimates last quarter?
In the previous quarter, Ultragenyx Pharmaceutical Inc. (:RARE) reported $-1.4 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.45 by $0.05.
-
How can I listen to Ultragenyx Pharmaceutical Inc.'s earnings conference call?
The conference call for Ultragenyx Pharmaceutical Inc.'s latest earnings report can be listened to online.
-
How can I read Ultragenyx Pharmaceutical Inc.'s conference call transcript?
The conference call transcript for Ultragenyx Pharmaceutical Inc.'s latest earnings report can be read online.
-
How much revenue does Ultragenyx Pharmaceutical Inc. generate each year?
Ultragenyx Pharmaceutical Inc. (:RARE) has a recorded annual revenue of $434.25 M.
-
How much profit does Ultragenyx Pharmaceutical Inc. generate each year?
Ultragenyx Pharmaceutical Inc. (:RARE) has a recorded net income of $434.25 M. Ultragenyx Pharmaceutical Inc. has generated $-8.25 earnings per share over the last four quarters.
-
What is Ultragenyx Pharmaceutical Inc.'s price-to-earnings ratio?
Ultragenyx Pharmaceutical Inc. (:RARE) has a price-to-earnings ratio of -8.07 and price/earnings-to-growth ratio is -0.71.
